Akero Therapeutics :
AKRO
AKRO
Stock Data
$54.65
$0.00 (0.00%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Akero Therapeutics Inc is a biotechnology firm focused on creating treatments for serious metabolic diseases, with a spotlight on metabolic dysfunction-associated steatohepatitis (MASH). Their leading product, efruxifermin, is advancing through Phase 3 clinical trials, aiming to regulate metabolism and protect against cellular stress. Originating as Pippin Pharmaceuticals and rebranded in 2018, Akero has partnered with Amgen Inc. for the development and distribution of its treatments. The company is based in South San Francisco, California, and was established in 2017.
All Akero Therapeutics Articles
2 Articles
